Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data. The biopharma revealed in ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The ALS drug that Amylyx pulled ...
Corcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in patients with amyotrophic lateral sclerosis did not meet the main goal. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results